Femtech

Funding into Femtech startups has grown nearly tenfold over the past five years, reaching $724M in 2025. With $238M raised in the first 5 months of 2026, the full year is on track to land at $570M, a -21% change versus 2025. The chart below shows annual funding totals; the latest year is annualised from observed-to-date data and represents the renderer's projection, not a closed quarter.

Yearly totals mask the quarter-by-quarter rhythm. The chart below shows Femtech startups funding raised in each of the last 21 complete quarters through Q1 2026. All bars are actual closed-quarter sums, no projections, no in-progress quarters.

Femtech's share of Health venture capital tracks how much of Health's startup capital lands in this market. In 2016, Femtech startups accounted for 2.0% of Health VC funding; by 2026 the share had reached 0.7%. The chart below splits each year's total Health VC funding into Femtech on the bottom and the rest of the market on top.

How capital deployed into Femtech startups is split across round sizes. In the trailing four quarters, 15% of capital landed in scaleup ($100M+) rounds, 67% in breakout ($15–100M), and 17% across startups (under $15M). Each panel below stacks the canonical sub-bands across Q1 2022 → Q1 2026.

The most active investors in Femtech startups ranked by the number of disclosed rounds they've participated in. Y Combinator leads with 40 rounds, followed by SOSV at 34. The table shows the top ten with their firm type, in-scope round count, total portfolio size, and headquarters.

Two views of leadership in Femtech startups: the most-funded companies all-time on the left, and the hottest companies right now by Dealroom Signal on the right. Total-funding figures include all capital sources tracked by Dealroom (VC plus grants, project finance, and other instruments). Signal is Dealroom's live growth ranking, these are the firms with the strongest recent momentum across team, timing, growth, and completeness.

United States leads global Femtech startups funding at $361M, followed by United Kingdom ($75M). The chart ranks the top countries; alongside it, the leading Bay Area metro region leads the city ranking with $185M. Use the metric pills, and the dropdown, to switch view. The VC dropdown also covers the fastest-growing hubs and where Femtech startups venture capital and unicorns concentrate against the rest of the world.

Where Femtech startups VC-backed startups are based. Each marker is sized by the number of VC-backed startups HQ'd in that metro. Bay Area leads at 64, followed by New York City at 55. Scroll or drag to explore, pinch with two fingers on mobile.

Over the last 12 months (through Jun 2026), the largest VC rounds in Femtech startups reveal where capital is consolidating. The table below lists the 15 biggest disclosed rounds by amount, with date, company, round type, and lead investors. Funding events without a public amount are excluded; acquisitions sit in the Unicorns & Exits section.

Which corners of Femtech are heating up fastest? Each sub-sector is scored on a transparent blend of two-year VC growth, unicorn formation, and recent funding scale. Menopause tops the ranking, with venture capital up 9% over three years to $104M in 2025 and 1 unicorns. Sub-sector tags overlap (a company can sit in several), so this shows where momentum concentrates rather than splitting the total.

Femtech startups have minted 13 unicorns to date. Dealroom defines a unicorn as a company that has reached a $1B+ valuation or exit (verified and manually reviewed; other lists use different criteria, this is ours). Of those, 0 are decacorns, companies at a $10B+ valuation. The ecosystem also counts 13 thoroughbreds: companies generating $100M+ in revenue (a separate lens from unicorns, with some overlap). The chart below shows the cumulative count climbing each year, with the line tracking new unicorns minted in that year, peaking at 3 in 2021. On exits, the sector has produced 67 tracked acquisitions since 2010 representing $3.8B in disclosed value. Notable acquisitions in the data include Eucalyptus ($1.1B, 2026), followed by KaNDy Therapeutics ($425M, 2020), HoneyPot Company ($380M, 2024).

Universities are the talent pipeline behind Femtech, the institutions whose alumni found the most unicorns and venture-backed companies, and the research that spins out into them.

The patent portfolio behind Femtech startups, granted patent families, where the IP concentrates, and the technologies driving it.